Evidence map›Paper›PMID 35497343›Full record

ReviewFrontiers in bioengineering and biotechnology2022

Triggering Immune System With Nanomaterials for Cancer Immunotherapy.

Qiyan Li, Yulin Liu, Zihua Huang, Yajie Guo, Qingjiao Li

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in bioengineering and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Advanced Human Immune Cell-Organoid Co-Cultures for Functional Testing of Cancer Nanovaccines.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. RSC advances · 2025
    Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Qiyan LiThe Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.
Yulin LiuThe Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.
Zihua HuangThe Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.
Yajie GuoThe Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.
Qingjiao LiThe Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.
Sun Yat-sen University · CNEighth Affiliated Hospital of Sun Yat-sen University

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is a major cause of incidence rate and mortality worldwide. In recent years, cancer immunotherapy has made great progress in the preclinical and clinical treatment of advanced malignant tumors. However, cancer patients will have transient cancer suppression reaction and serious immune related adverse reactions when receiving immunotherapy. In recent years, nanoparticle-based immunotherapy, which can accurately deliver immunogens, activate antigen presenting cells (APCs) and effector cells, provides a new insight to solve the above problems. In this review, we discuss the research progress of nanomaterials in immunotherapy including nanoparticle-based delivery systems, nanoparticle-based photothermal and photodynamic immunotherapy, nanovaccines, nanoparticle-based T cell cancer immunotherapy and nanoparticle-based bacteria cancer immunotherapy. We also put forward the current challenges and prospects of immunomodulatory therapy.

Indexed as

cancer immunotherapydelivery systemnanomaterialsnanovaccinesphotodynamic immunotherapyphotothermal immunotherapy

Identifiers

PMID35497343
PMCPMC9046726
OpenAlexW4223914026

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.